Your browser doesn't support javascript.
Adverse Events and Serological Responses After SARS-CoV-2 Vaccination in Individuals With Inflammatory Bowel Disease.
Markovinovic, Ante; Quan, Joshua; Herauf, Michelle; Hracs, Lindsay; Windsor, Joseph W; Sharifi, Nastaran; Coward, Stephanie; Caplan, Léa; Gorospe, Julia; Ernest-Suarez, Kenneth; Ma, Christopher; Panaccione, Remo; Ingram, Richard J M; Kanji, Jamil N; Tipples, Graham; Holodinsky, Jessalyn K; Bernstein, Charles N; Mahoney, Douglas J; Bernatsky, Sasha; Benchimol, Eric I; Kaplan, Gilaad G.
  • Markovinovic A; Inflammatory Bowel Disease Clinic, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Quan J; Inflammatory Bowel Disease Clinic, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Herauf M; Inflammatory Bowel Disease Clinic, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Hracs L; Inflammatory Bowel Disease Clinic, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Windsor JW; Inflammatory Bowel Disease Clinic, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Sharifi N; Inflammatory Bowel Disease Clinic, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Coward S; Inflammatory Bowel Disease Clinic, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Caplan L; Inflammatory Bowel Disease Clinic, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Gorospe J; Inflammatory Bowel Disease Clinic, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Ernest-Suarez K; Inflammatory Bowel Disease Clinic, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Ma C; Inflammatory Bowel Disease Clinic, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Panaccione R; Inflammatory Bowel Disease Clinic, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Ingram RJM; Inflammatory Bowel Disease Clinic, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Kanji JN; Alberta Precision Laboratories, Public Health Laboratory, Alberta, Canada.
  • Tipples G; Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada.
  • Holodinsky JK; Division of Infectious Diseases, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Bernstein CN; Alberta Precision Laboratories, Public Health Laboratory, Alberta, Canada.
  • Mahoney DJ; Department of Medical Microbiology and Immunology, Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada.
  • Bernatsky S; Department of Clinical Neuroscience, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Benchimol EI; University of Manitoba IBD Clinical and Research Centre and Department of Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
  • Kaplan GG; Department of Microbiology, Immunology and Infectious Disease, University of Calgary, Calgary, Alberta, Canada.
Am J Gastroenterol ; 2023 Jun 26.
Article in English | MEDLINE | ID: covidwho-2324748
ABSTRACT

INTRODUCTION:

We determined adverse events after 4 doses of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine in those with inflammatory bowel disease (IBD), associations between antibodies and injection site reactions (ISR), and risk of IBD flare.

METHODS:

Individuals with IBD were interviewed for adverse events to SARS-CoV-2 vaccine. Multivariable linear regression assessed the association between antibody titers and ISR.

RESULTS:

Severe adverse events occurred in 0.03%. ISR were significantly associated with antibody levels after the fourth dose (geometric mean ratio = 2.56; 95% confidence interval 1.18-5.57). No cases of IBD flare occurred.

DISCUSSION:

SARS-CoV-2 vaccines are safe for those with IBD. ISR after the fourth dose may indicate increased antibodies.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines Language: English Year: 2023 Document Type: Article Affiliation country: Ajg.0000000000002337

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines Language: English Year: 2023 Document Type: Article Affiliation country: Ajg.0000000000002337